Increased vessel perfusion predicts the efficacy of immune checkpoint blockade

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×

The future of immune checkpoint therapy

Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878

Molecular mechanisms of T cell co-stimulation and co-inhibition

Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839

The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies

Melaiu, O., Vanni, G., Portarena, I., Pistolese, C. A., Anemona, L., Pomella, S., Bei, R., Buonomo, O. C., Roselli, M., Mauriello, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043226 · Cited by 26

Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma

Xu, K., Gu, T., Su, K., Liu, X., He, B., He, J., Chi, H., Zhou, X., Liu, H., Xiao, R., et al. (2025) · Discover Oncology · doi:10.1007/s12672-025-02914-4 · Cited by 26

Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine

Hagan, C. T., Mi, Y., Knape, N. M., & Wang, A. Z. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00520 · Cited by 24

Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models

Li, Z.-J., He, B., Domenichini, A., Satiaputra, J., Wood, K. H., Lakhiani, D. D., Bashaw, A. A., Nilsson, L. M., Li, J., Bastow, E. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179860 · Cited by 26

Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer

Fang, L., Zhao, W., Ye, B., & Chen, D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670313 · Cited by 23

Inducing vascular normalization: A promising strategy for immunotherapy

Luo, X., Zou, W., Wei, Z., Yu, S., Zhao, Y., Wu, Y., Wang, A., & Lu, Y. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109167 · Cited by 25

Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019

Cantelmo, A. R., Dejos, C., Kocher, F., Hilbe, W., Wolf, D. G. F., & Pircher, A. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000591 · Cited by 23

Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors

Kim, D. J., Anandh, S., Null, J. L., Przanowski, P., Bhatnagar, S., Kumar, P., Shelton, S. E., Grundy, E. E., Chiappinelli, K. B., Kamm, R. D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37807-z · Cited by 24

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions

Jiang, M., Hu, Y., Lin, G., Chen, C., & Li, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1177085 · Cited by 23

Blood-Based Biomarkers as Predictive and Prognostic Factors in Immunotherapy-Treated Patients with Solid Tumors—Currents and Perspectives

Kaczmarek, F., Marcinkowska‐Gapińska, A., Bartkowiak-Wieczorek, J., Nowak, M., Kmiecik, M., Brzezińska, K., Dotka, M., Brosz, P., Firlej, W., & Wojtyła-Buciora, P. (2025) · Cancers · doi:10.3390/cancers17122001 · Cited by 20

Combined Application of Bevacizumab and Pd-1 Blockade Displays Durable Treatment Effects by Increasing the Infiltration And Cytotoxic Function of Cd8 + T Cells in Lung Cancer

Liu, Y., Zhang, T., Zhang, L., Zhao, C., Zhang, Z., Wang, Z., Gu, M., Li, W., & Li, B. (2022) · Immunotherapy · doi:10.2217/imt-2021-0196 · Cited by 20

Towards Immunotherapy-Induced Normalization of the Tumor Microenvironment

Melo, V. A., Bremer, E., & Martin, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.908389 · Cited by 20

Vascular damage in tumors: a key player in stereotactic radiation therapy?

Kozin, S. V. (2022) · Trends in cancer · doi:10.1016/j.trecan.2022.06.002 · Cited by 21

New insight in immunotherapy and combine therapy in colorectal cancer

Ji, K., Jia, H., Liu, Z., Yu, G., Wen, R., Zhang, T., Peng, Z., Man, W., Tian, Y., Wang, C., et al. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1453630 · Cited by 22

The synergistic potential of mechanotherapy and sonopermeation to enhance cancer treatment effectiveness

Neophytou, C., Stylianopoulos, T., & Mpekris, F. (2025) · npj Biological Physics and Mechanics. · doi:10.1038/s44341-025-00017-3 · Cited by 20

Artificial intelligence–enabled multi-omics biomarkers for immune checkpoint blockade: mechanisms, predictive modeling, and clinical translation

Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1732079 · Cited by 22

Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature

Subudhi, S., Lee, S., & Jain, R. K. (2026) · Cell · doi:10.1016/j.cell.2026.03.016 · Cited by 29

Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response

Kaffas, A. E., Hoogi, A., Zhou, J., Durot, I., Wang, H., Rosenberg, J., Tseng, A., Sagreiya, H., Akhbardeh, A., Rubin, D. L., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-63810-1 · Cited by 17

Anlotinib combined with the PD-L1 blockade exerts the potent anti-tumor immunity in renal cancer treatment

Li, J., Cao, P., Chen, Y., Wang, J., Sun, X., Chen, R., Wang, G., & Hou, J. (2022) · Experimental Cell Research · doi:10.1016/j.yexcr.2022.113197 · Cited by 17

Combined Blockade of GARP:TGF-β1 and PD-1 Increases Infiltration of T Cells and Density of Pericyte-Covered GARP+ Blood Vessels in Mouse MC38 Tumors

Bertrand, C., Meerbeeck, P. V., de Streel, G., Vaherto, N., Benhaddi, F., Rouaud, L., Noël, A., Coulie, P. G., van Baren, N., & Lucas, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.704050 · Cited by 17

Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside

Abdel‐Aziz, A. K., Saadeldin, M. K., D’Amico, P., Orecchioni, S., Bertolini, F., Curigliano, G., & Minucci, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.013 · Cited by 17

Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition

Martin, J. D., Lanning, R. M., Chauhan, V. P., Martin, M. R., Mousa, A. S., Kamoun, W. S., Han, H., Lee, H., Stylianopoulos, T., Bawendi, M. G., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0486 · Cited by 16

Targeting circulating tumor cells to prevent metastases

Gostomczyk, K., Marsool, M. D. M., Tayyab, H., Pandey, A., Borowczak, J., Macome, F., Chacón, J. A., Dave, T., Maniewski, M., & Szylberg, Ł. (2023) · Human Cell · doi:10.1007/s13577-023-00992-6 · Cited by 16

Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial

Wu, J., Zhang, S., Yu, S., An, G., Wang, Y., Yu, Y., Liang, L., Wang, Y., Xu, X., Xiong, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53109-4 · Cited by 16

Low-dose X-ray irradiation combined with FAK inhibitors improves the immune microenvironment and confers sensitivity to radiotherapy in pancreatic cancer

Chen, H., Tu, W., Lu, Y., Zhang, Y., Xu, Y., Chen, X., Zhu, M., & Liu, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113114 · Cited by 16

Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma

Yin, Z., Zhang, H., Zhang, K., Yue, J., Tang, R., Wang, Y., Deng, Q., & Yu, Q. (2025) · BMC Cancer · doi:10.1186/s12885-025-13801-0 · Cited by 16

Targeting the mechano-microenvironment and liver cancer stem cells: a promising therapeutic strategy for liver cancer

Fu, X., Zhang, Y., Luo, Q., Ju, Y., & Song, G. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0229 · Cited by 14

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

Wang, Y., Lu, J., Chong, X., Wang, C., Chen, X., Peng, Z., Gu, Y., Wang, Y., Wang, X., Li, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02193-z · Cited by 17

Combination of Immunotherapy and Antiangiogenic Therapy in Cancer—a Rational Approach

Padda, S. K., & Reckamp, K. L. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.007 · Cited by 15

Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play

Donlon, N. E., Power, R. F., Hayes, C., Davern, M., Reynolds, J. V., & Lysaght, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031071 · Cited by 15

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer

Chen, Y., Liu, X., Huang, Z., Zhao, K., Wang, Y., Ren, F., Yu, J., & Meng, X. (2021) · Cancer Medicine · doi:10.1002/cam4.4363 · Cited by 14

High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers

Fan, P., Qi, Z., Liu, Z., Wang, S., Wang, Y., Kuai, J., Zhang, N., Xu, W., Qin, S., Candi, E., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07471-w · Cited by 14

Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy

Hoffmann, E., Gerwing, M., Krähling, T., Hansen, U. J., Kronenberg, K., Masthoff, M., Geyer, C., Höltke, C., Wachsmuth, L., Schinner, R., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01658-9 · Cited by 14

Anti‐cathepsin D immunotherapy triggers both innate and adaptive anti‐tumour immunity in breast cancer

David, T., Mallavialle, A., Faget, J., Alcaraz, L. B., Lapierre, M., du Roure, P. D., Laurent‐Matha, V., Mansouri, H., Jarlier, M., Martineau, P., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16291 · Cited by 14

Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy

Meo, C., & de Nigris, F. (2024) · Cancers · doi:10.3390/cancers16030491 · Cited by 14

GraphMHC: Neoantigen prediction model applying the graph neural network to molecular structure

Jeong, H., Cho, Y.-R., Gim, J., Cha, S.-K., Kim, M., & Kang, D. R. (2024) · PLOS ONE · doi:10.1371/journal.pone.0291223 · Cited by 14

Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltration

Liu, A. J., Gammon, S. T., Pisaneschi, F., Boda, A. R., Ager, C. R., Piwnica-Worms, D. R., Hong, D. S., & Curran, M. A. (2023) · JCI Insight · doi:10.1172/jci.insight.169150 · Cited by 15

Promoting Nanoparticle Delivery Efficiency to Tumors by Locally Increasing Blood Flow There

Fan, F., Xie, B., & Yang, L. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00871 · Cited by 14

Tumor vessel normalization and immunotherapy in gastric cancer

Yu, X., He, S., Shen, J., Huang, Q., Peng, Y., Huang, L., Pu, D., Wang, L., Li, L., Liu, J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221110176 · Cited by 15

Electroacupuncture normalized tumor vasculature by downregulating glyoxalase-1 to polarize tumor-associated macrophage to M1 phenotype in triple-negative breast cancer

Qi, X., Lian, Y., Fan, Z., Wang, H., Jiang, H., He, M., Li, L., Huang, J., & Wan, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113988 · Cited by 12

Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade

Blanchard, L., Vina, E., Ljubetic, J., Meneur, C., Tarroux, D., Baez, M., Marino, A. E., Ortéga, N., Knorr, D. A., Ravetch, J. V., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102141 · Cited by 14

Integration of immune and hypoxia gene signatures improves the prediction of radiosensitivity in breast cancer.

Yan, D., Cai, S., Bai, L., Du, Z., Li, H., Sun, P., Cao, J., Yi, N., Liu, S., & Tang, Z. (2022) · PubMed Central · Cited by 12

Autophagy-related IFNG is a prognostic and immunochemotherapeutic biomarker of COAD patients

Yue, T., Cai, Y., Zhu, J., Liu, Y., Chen, S., Wang, P., & Rong, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1064704 · Cited by 12

Non-hematopoietic Control of Peripheral Tissue T Cell Responses: Implications for Solid Tumors

Lane, R. S., & Lund, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02662 · Cited by 12

Tailoring therapies to counter the divergent immune landscapes of breast cancer

Attalla, S. S., Taifour, T., & Muller, W. J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1111796 · Cited by 13

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer

Liu, H., Capuani, S., Badachhape, A., Trani, N. D., Gonzalez, D. D., Pol, R. V., Viswanath, D. I., Saunders, S. Z., Hernandez, N., Ghaghada, K. B., et al. (2023) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10594 · Cited by 10

Magnetic resonance imaging-based approaches for detecting the efficacy of combining therapy following VEGFR-2 and PD-1 blockade in a colon cancer model

Xu, X. Z., Ma, M., Ye, K., Zhang, D., Chen, X., Wu, J., Mo, X., Xiao, Z., Shi, C., & Luo, L. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04975-5 · Cited by 11

IFNγ blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins

Wang, R., Ni, C., Lou, X., Zhang, L., Wang, L., Yao, X., Duan, X., Wan, J., Li, P., & Qin, Z. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78248 · Cited by 10

Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions

Weishan, H., Dong-lin, Z., Guangmei, D., Liu, W., Wu, F., & Chen, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03337-9 · Cited by 10

Emerging innovations in nanomedicine for cancer immunotherapy

Shah, J. R., Kapoor, D. U., & Prajapati, B. G. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106584 · Cited by 11

Pericyte phenotype switching in cancer

He, B., & Ganß, R. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.06.005 · Cited by 11

Combination of immune checkpoint inhibitors and anti-angiogenic agents: An emerging strategy for cancer therapy

Li, Y., Yang, L., & Zd, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104883 · Cited by 11

Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment

Zhu, D., Su, C., Li, J. J., Li, A. W., Luv, Y., & Fan, Q. (2023) · World Journal of Oncology · doi:10.14740/wjon1645 · Cited by 10

Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study

Li, L., Wang, T., Wu, Z., Li, Y., Ma, H., Wang, L., Lei, S., & Chen, W. (2023) · Translational Cancer Research · doi:10.21037/tcr-23-867 · Cited by 10

Endogenous pAKT activity is associated with response to AKT inhibition alone and in combination with immune checkpoint inhibition in murine models of TNBC

Bullock, K. K., Shattuck-Brandt, R. L., Scalise, C. B., Luo, W., Chen, S., Saleh, N., Ericsson, P. I. G., Garcia, G., Sanders, M. E., Ayers, G. D., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216681 · Cited by 10

A bibliometric analysis of drug resistance in immunotherapy for breast cancer: trends, themes, and research focus

Zhang, R., Jiang, Q., Zhuang, Z., Zeng, H., & Li, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1452303 · Cited by 9

Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy

Nikoo, M., Hassan, Z. F., Mardasi, M., Rostamnezhad, E., Roozbahani, F., Rahimi, S., & Mohammadi, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154473 · Cited by 9

A contrast-enhanced ultrasound-based nomogram for the prediction of therapeutic efficiency of anti-PD-1 plus anti-VEGF agents in advanced hepatocellular carcinoma patients

Sun, C., Wang, Q., Hou, L., Zhang, R., Chen, Y., & Niu, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1229560 · Cited by 9

Targeting the pericyte antigen DLK1 with an alpha type-1 polarized dendritic cell vaccine results in tumor vascular modulation and protection against colon cancer progression

McCormick, A. L., Anderson, T. S., Daugherity, E. A., Okpalanwaka, I. F., Smith, S. L., Appiah, D., & Lowe, D. B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1241949 · Cited by 9

Lymphocyte homing and recirculation with tumor tertiary lymphoid structure formation: predictions for successful cancer immunotherapy

Tian, W., Wei, W., Qin, G., Bao, X., Tong, X., Zhou, M., Xue, Y. C., Zhang, Y. L., & Shao, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1403578 · Cited by 13

Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy

Zheng, X., Kuai, J., & Shen, G. (2023) · Immunotherapy · doi:10.2217/imt-2022-0254 · Cited by 9

Advances of ultrasound in tumor immunotherapy

Lin, J., Wu, Y., Liu, G., Cui, R., & Xu, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112233 · Cited by 8

Combining immunotherapy and radiation therapy in gastrointestinal cancers: A review

Mitrea, D. A., Froicu, E.-M., Prenen, H., Gambacorta, M. A., Span, P. N., & Poortmans, P. M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104381 · Cited by 8

Immune priming and induction of tertiary lymphoid structures in a cord-blood humanized mouse model of gastrointestinal stromal tumor

He, B., Dymond, L., Wood, K. H., Bastow, E. R., Satiaputra, J., Li, J., Johansson, A., Hamzah, J., Kumarasinghe, P. M., Ballal, M., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2406576 · Cited by 7

Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [18F]FMISO

Nakajima, K., Homma, M., Suzuki, M., Yokouchi, Y., Matsuda, T., Takakura, H., Hirata, K., Kuge, Y., & Ogawa, M. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.03.005 · Cited by 7

Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers

Cheng, S., Li, B., Yu, J., & Wang, L. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.05.06 · Cited by 7

Augmentation of tumour perfusion by ultrasound and microbubbles: A preclinical study

Zhang, J., Zhang, Y., Cai, Z., Wei, J., Li, H., Li, P., Dong, X., & Liu, Z. (2023) · Ultrasonics · doi:10.1016/j.ultras.2023.107219 · Cited by 7

Novel myeloma patient-derived xenograft models unveil the potency of anlotinib to overcome bortezomib resistance

Yue, Y., Cao, Y., Mao, X., Wang, F., Fan, P., Qian, L., Guo, S., Li, F., Guo, Y., Chen, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894279 · Cited by 8

Engineered platelet-based immune engager for tumor post-surgery treatment

Chen, M., Zhang, J., Li, H., Deng, Y., Huang, Y., Shen, W., Zeng, Y., & Ci, T. (2024) · Biomaterials Advances · doi:10.1016/j.bioadv.2024.213796 · Cited by 6

Baseline tumour vessel perfusion as a non-invasive predictive biomarker for immune checkpoint therapy in non-small-cell lung cancer

Liu, Z., Ma, K., Jia, Q., Yang, Y., Fan, P., Wang, Y., Wang, J., Sun, J., Sun, L., Shi, H., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000473 · Cited by 6

Spatial frequency domain imaging for monitoring immune-mediated chemotherapy treatment response and resistance in a murine breast cancer model

Tank, A., Vergato, C., Waxman, D. J., & Roblyer, D. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-09671-2 · Cited by 6

The role of DLL1 in long-term vascular normalization and cancer immunotherapy

Wu, Q., & Huang, Y. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0507 · Cited by 6

Integration of single-cell and spatial transcriptome sequencing identifies CDKN2A as a senescent biomarker in endothelial cells implicating hepatocellular carcinoma malignancy

Ma, Y., Yi, C., Cai, N., & Chen, J. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-06017-5 · Cited by 5

Pretreatment CT-Based Machine Learning Radiomics Model Predicts Response in Inoperable Stage III NSCLC Treated with Concurrent Radiochemotherapy Plus PD-1 Inhibitors

Li, Y., Zhang, M., Hu, Y., Du, B., Mo, Y., He, T., Zhao, M., Li, B., Xia, J., Huang, Z., et al. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251351109 · Cited by 6

The efficacy and safety of short-course radiotherapy followed by sequential chemotherapy and Cadonilimab for locally advanced rectal cancer: a protocol of a phase II study

Xu, T., Feng, L., Zhang, W., Li, H., Ma, H., Abulimiti, M., Tan, Y., Deng, F., Huang, W., Zou, S., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-12254-1 · Cited by 5

Combining an adenovirus encoding human endostatin and PD‐1 blockade enhanced antitumor immune activity

Tian, Y., Hu, Q., Zhang, R., Zhou, B., Xie, D., Wang, Y., & Yang, L. (2023) · MedComm – Oncology · doi:10.1002/mog2.21 · Cited by 5

Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy

Zhang, Y., Gao, J., He, Y., Qi, Z., Qian, L., Chen, W., Xu, H., Yue, Y., Mao, X., Guo, S., et al. (2023) · Journal of Immunology Research · doi:10.1155/2023/5867047 · Cited by 5

Human intravital microscopy in the study of sarcomas: an early trial of feasibility

Gabriel, E. M., Sukniam, K., Popp, K., & Bagaria, S. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1151255 · Cited by 5

An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC

Wang, H., Hu, L., Zhang, F., Fang, M., Xu, J., Li, M., & Chen, Z. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.106814 · Cited by 5

Evaluating the impact of treatment sequencing on outcomes in hepatocellular carcinoma: a comparative analysis of TACE and systemic therapies

Zheng, X., Song, X., Zhang, B., Chen, X., Zhang, Y., Luo, Q., Li, Z., Deng, Z., Xu, R., Peng, L., et al. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01500-2 · Cited by 4

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review

Yan, Z., Yao, Z.-H., Yao, S.-N., Xia, Q.-X., Wang, H.-Y., Chu, J., Song, M., Zhao, S., & Liu, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s254007 · Cited by 5

Normalizing the Tumor Microenvironment for Radiosensitization

Martin, J. D., & Jain, R. K. (2020) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-030-49701-9_12 · Cited by 5

Multi-omics analysis of the biological function of the VEGF family in colon adenocarcinoma

Yang, J., Li, C., Wang, Z., & Jiang, K. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01493-x · Cited by 4

Immunotherapy and radiotherapy: An effective combination in cancer treatment

Li, X., Wang, C., Yang, H., Xue, W., Ding, Y.-Q., Wu, N., Pei, B., Ma, X., & Yang, W. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003609 · Cited by 5

Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study

Onuoha, E. E., Smith, A. D., Cannon, R. M., Khushman, M. M., & Kim, H. (2022) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00858-4 · Cited by 4

Normalization of the tumor vasculature

Klein, D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-816196-8.00015-1 · Cited by 3

Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy

Jarrett, A. M., Song, P. N., Reeves, K. M., Lima, E. A. B. F., Larimer, B. M., Yankeelov, T. E., & Sorace, A. G. (2023) · Mathematical Biosciences · doi:10.1016/j.mbs.2023.109106 · Cited by 3

A review on Biomarkers for predicting radioresistance and role of natural radiosensitizers in Triple-Negative Breast Cancer

Mehta, D., Brahmbhatt, J., Bhadresha, K. P., & Rawal, R. (2023) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2023.150418 · Cited by 2

Efficacy and safety of concurrent programmed cell death protein 1 inhibitor and definitive radiotherapy with immunonutrition support in esophageal squamous cell cancer: a phase II multicenter clinical trial

Yuan, Y., Luo, S., Wang, X., Zheng, Z., Qi, Q., Wang, Y., Chen, M., Yang, H., Gu, P., Du, Q., et al. (2025) · Radiation Oncology · doi:10.1186/s13014-025-02604-z · Cited by 3

Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era

Zheng, J., Zheng, Z., Zhang, T., Chen, X., Pang, Q., Wang, P., Yan, C., & Zhang, W. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2423009 · Cited by 2

Integrative Multi‐Omics Analysis Uncovers Immunological Phenotypes Predictive of Combinatorial Immunotherapy Response in Gastric Cancer

Wang, J., Zhang, W., Zhang, J., Zhao, C., Zhang, W., Fang, M., Chen, F., Wu, Z., Xu, X., Yu, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202514482 · Cited by 6

Patient-derived geometry-integrated multiphysics framework: Computational optimization of immunotherapeutic nanoparticle delivery via tumor microenvironment reprogramming in prostate cancer

Mirala, F., & Soltani, M. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111388 · Cited by 2

Effectiveness and mechanisms of lymphocytes at different time points in predicting consolidation immunotherapy following adaptive chemoradiotherapy in locally advanced non-small cell lung cancer

Sun, Z. W., Duan, J., Zhang, Z., Chen, M., Zhou, D., Hou, L., Gu, P., Zhu, J., Yang, H., & Zhou, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1683430 · Cited by 2

Potential efficacy of local therapy for progressive lesions after nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Sato, M., Enokida, T., Wada, A., Okano, S., Tanaka, H., Fujisawa, T., Ueda, Y., Motegi, A., Shinozaki, T., Takeshita, N., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02351-9 · Cited by 2

A Three-agent Regimen for Triple Negative Breast Cancer Treatment

Wang, S., Huang, C., Zhu, Y., Wang, M., Wang, W., Liu, C., & Su, W. (2025) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/0115748928350267250105153944 · Cited by 2

Tumor Angiogenesis

Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2

Sequential immunotherapy and bevacizumab treatments in glioblastoma multiforme: A case series and review of the literature

Kertmen, N., Kavgacı, G., Koc, I., SAĞOL, Ş. P., Işıkay, A. İ., & Yazıcı, G. (2025) · Oncology Letters · doi:10.3892/ol.2025.14892 · Cited by 1

The evaluation of the efficacy and safety about apatinib combined with immune checkpoint inhibitors in advanced gastric cancer: a real-world study

Zhu, P.-F., Yang, L., & Chen, Z.-L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578011 · Cited by 1

From bench to bedside: the development journey of fruquintinib as a colorectal cancer therapy

Román, M. S., Zumstein, L., Zappi, A., Modrego-Sánchez, A., Soldevilla, B., & García‐Carbonero, R. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2530597 · Cited by 1

Tumor Microcirculation: Abnormalities and Normalization

Fukumura, D. (2025) · Physiology in health and disease · doi:10.1007/978-3-031-99609-2_13 · Cited by 1

CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils

Zheng, X., Zhang, N., Qian, L., Wang, X., Fan, P., Kuai, J., Lin, S., Liu, C., Jiang, W., Qin, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32829 · Cited by 76

VCAM-1 Density and Tumor Perfusion Predict T-cell Infiltration and Treatment Response in Preclinical Models

Riegler, J., Gill, H. S., Ogasawara, A. K., Hedehus, M., Javinal, V., Oeh, J., Ferl, G. Z., Mařı́k, J., Williams, S. P., Sampath, D., et al. (2019) · Neoplasia · doi:10.1016/j.neo.2019.08.003 · Cited by 47

Unlocking the predictive power of imaging biomarkers: predicting immune checkpoint therapy response in non-small cell lung cancer through baseline tumour vessel perfusions

Dubash, S., & Tsang, Y. M. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000539

Improved Tumor Blood Flow Enhances the Abscopal Effect: Preclinical Assessment in Mice Treated with Combined Radiation and PD-1 Blockade TherapyPreprint

Yamashita, K., Brender, J., Saida, Y., Otowa, Y., Kazumasa, H., Ito, T., Yamamoto, K., Merkle, H., Linehan, W. M., Krishna, M. C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.04.652150 · Cited by 2

Advanced imaging to assess longitudinal vascular changes in brain metastases treated with immune checkpoint inhibition.

Kim, A. E., Chang, K., Beers, A. L., Emblem, K. E., Kalpathy–Cramer, J., Lee, E. Q., Lin, N., Nayak, L., Chukwueke, U. N., Oh, K. S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.2529